Literature DB >> 7923123

A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene.

W Yue1, D Zhou, S Chen, A Brodie.   

Abstract

MCF-7 cells transfected with human placental aromatase gene (MCF-7Ca cells) or cells transfected with plasmid vector only (MCF-7Cc cells) were inoculated into nude mice with Matrigel. Tumors formed from both MCF-7Ca and MCF-7Cc cells grew faster in intact mice than in ovariectomized mice, suggesting that the tumors maintained their responsiveness to estrogen stimulation and that their growth was supported by ovarian estrogen. Injections of androstenedione (0.1 mg/mouse/day) to provide the substrate for aromatization to ovariectomized mice bearing MCF-7Ca tumors accelerated their growth but did not affect growth of MCF-7Cc tumors. This result indicates that local production of estrogen by intratumoral aromatase was sufficient to stimulate tumor growth. When ovariectomized mice with MCF-7Ca tumors supplemented with androstenedione were treated with aromatase inhibitors 4-hydroxyandrostenedione (1 mg/mouse/day, s.c.) or CGS 16949A (0.5 mg/mouse/day, s.c.), or with the antiestrogen tamoxifen (10 micrograms/mouse/day, s.c.), tumor growth was significantly inhibited. Tumor aromatase activity measured at the end of treatment was also inhibited by 4-hydroxyandrostenedione when the mice were sacrificed 4 h after the last injection. The tumors of this mouse model are dependent for their growth on estrogens from an endogenous nonovarian source. Thus, it simulates the situation in the postmenopausal breast cancer patient and could be used to evaluate the effect of aromatase inhibitors and antiestrogens.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923123

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Aromatase and breast cancer.

Authors:  A Brodie; G Sabnis; D Jelovac
Journal:  J Steroid Biochem Mol Biol       Date:  2006-12       Impact factor: 4.292

2.  Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women.

Authors:  Monica Milani; Gautam Jha; David A Potter
Journal:  Clin Med Ther       Date:  2009-03-31

3.  Inhibition of estrogen-induced mammary tumor formation in MMTV-aromatase transgenic mice by 4-chlorophenylacetate.

Authors:  Neil Sidell; Nameer Kirma; Eddie T Morgan; Hareesh Nair; Rajeshwar Rao Tekmal
Journal:  Cancer Lett       Date:  2007-01-09       Impact factor: 8.679

4.  Steroid receptor coactivator 3 regulates autophagy in breast cancer cells through macrophage migration inhibitory factor.

Authors:  Mei-Yi Wu; Junjiang Fu; Jianming Xu; Bert W O'Malley; Ray-Chang Wu
Journal:  Cell Res       Date:  2012-03-20       Impact factor: 25.617

Review 5.  Aromatase inhibitors in the treatment of postmenopausal breast cancer.

Authors:  E Bajetta; N Zilembo; E Bichisao
Journal:  Drugs Aging       Date:  1999-10       Impact factor: 3.923

6.  Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy.

Authors:  James N Ingle; Fang Xie; Matthew J Ellis; Paul E Goss; Lois E Shepherd; Judith-Anne W Chapman; Bingshu E Chen; Michiaki Kubo; Yoichi Furukawa; Yukihide Momozawa; Vered Stearns; Kathleen I Pritchard; Poulami Barman; Erin E Carlson; Matthew P Goetz; Richard M Weinshilboum; Krishna R Kalari; Liewei Wang
Journal:  Cancer Res       Date:  2016-10-10       Impact factor: 12.701

7.  HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.

Authors:  Gauri J Sabnis; Olga G Goloubeva; Armina A Kazi; Preeti Shah; Angela H Brodie
Journal:  Mol Cancer Ther       Date:  2013-10-03       Impact factor: 6.261

8.  Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment.

Authors:  Gauri Sabnis; Olga Goloubeva; Rabia Gilani; Luciana Macedo; Angela Brodie
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

9.  Heptamethine cyanine based (64)Cu-PET probe PC-1001 for cancer imaging: synthesis and in vivo evaluation.

Authors:  Li Xiao; Yi Zhang; Wei Yue; Xiuzhen Xie; Ji-Ping Wang; Mahendra D Chordia; Leland W K Chung; Dongfeng Pan
Journal:  Nucl Med Biol       Date:  2013-02-01       Impact factor: 2.408

10.  Improving Therapeutic Potential of Farnesylthiosalicylic Acid: Tumor Specific Delivery via Conjugation with Heptamethine Cyanine Dye.

Authors:  Yang Guan; Yi Zhang; Li Xiao; Jie Li; Ji-Ping Wang; Mahendra D Chordia; Zhong-Qiu Liu; Leland W K Chung; Wei Yue; Dongfeng Pan
Journal:  Mol Pharm       Date:  2016-12-16       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.